 NEWTON, Mass., April 26, 2021 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq: KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency EMA has validated the Companys Type II Variation Marketing Authorization Application MAA, which seeks to expand the currently authorized indication for NEXPOVIO in the European Union to include, in combination with Velcade bortezomib and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. 